Research programme: RNA therapeutics - Riboxx Pharmaceuticals

Drug Profile

Research programme: RNA therapeutics - Riboxx Pharmaceuticals

Alternative Names: Apoxxim; RGC 1; RGC L1; RGC L2; RGIC 1; RIBOXXIM®; RIBOXXON®

Latest Information Update: 18 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Riboxx Pharmaceuticals
  • Developer Riboxx Pharmaceuticals; TOLLYS SAS
  • Class Drug conjugates; RNA
  • Mechanism of Action DDX58 protein modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer; Viral infections

Highest Development Phases

  • Preclinical Cancer; Viral infections
  • Research Autoimmune disorders

Most Recent Events

  • 18 Feb 2016 RNA therapeutics - Riboxx Pharmaceuticals is available for licensing in World as of 18 Feb 2016.
  • 18 Feb 2016 Riboxx Pharmaceuticals has patents pending for Riboxxim® platform in USA and European Union (Riboxx Pharmaceuticals website, February 2016)
  • 18 Feb 2016 Riboxx Pharmaceuticals plans a phase I/IIa trial for Viral infection in Germany (Riboxx Pharmaceuticals website, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top